Rivus Pharmaceuticals

Rivus Pharmaceuticals is committed to improving cardiometabolic health by developing Controlled Metabolic Accelerators (CMA) to address the underlying metabolic risk factors of cardiovascular mortality and morbidity. Rivus's Controlled Metabolic Accelerator (CMA) is an oral small-molecule therapy designed to effectively target the root causes of metabolic diseases, namely the accumulation of fat and sugar in the body. It addresses the fundamental causes of cardiometabolic diseases by leveraging the body’s natural processes to enhance cellular metabolism. Rivus’s therapy presents a significant opportunity to help patients achieve better health outcomes when facing a wide range of cardiometabolic conditions, including type 2 diabetes, hypertension, non-alcoholic steatohepatitis (NASH), dyslipidemia, and obesity.